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The polymerase chain reaction (PCR) (1) has found wide application in identifying gene mutations in patients with genetic diseases. It is often useful to test the effect of specific mutations on gene expression in vitro. We describe a PCR protocol to rapidly and efficiently introduce specific mutations found in patient material into cloned DNA using double-stranded PCR fragments containing the mutations of interest. The procedure uses a double-stranded PCR product amplified from an M13 clone containing a mutation as one primer and an oligonucleotide derived from another exon of the gene as a second primer to generate a PCR product that can then be easily cloned into the desired vector.
We identified two mutations in exon 4 of the tyrosinase gene in patients with tyrosinase-negative oculocutaneous albinism (unpublished data). To test the effect of these mutations on tyrosinase enzyme activity we introduced them into a tyrosinase cDNA for in vitro expression. Exon 4 (182 bp) was amplified by PCR from DNA (30 ng) of two M13 exon 4 subclones containing either of the two mutations in 100 ^1 volumes of 10 mM TrisHCl pH 8.3, 50 raM KC1, 1.5 raM MgCl 2 , 200 yM of each dNTP, 100 /tg/ml gelatin, 100 pmoles of both exon 4 primers (derived from the very 5' and 3' ends of exon 4), and 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT) using an automated thermal cycler (Coy Laboratory Products Inc., Ann Arbor, MI). Each of the 30 cycles consisted of 30 sec at 94, 2 min at 50, and 2 min at 72 °C. We then amplified a 547-bp exon 2-3-4 product from 30 ng of tyrosinase cDNA using as one primer 5 pmoles of the gel-purified mutant exon 4 PCR product and a 20mer oligonucleotide derived from the 5' end of exon 2 as the second (Fig.) . This mutant exon 2-3-4 PCR product contained unique restriction sites in exons 2 and 4 that facilitated cloning into a previously constructed tyrosinase cDNA expression plasmid. All recombinants analyzed contained the desired mutations.
The efficiency of 'site-directed mutagenesis' by this procedure is 100 percent and obviates the need for synthesis of a new PCR oligonucleotide primer for each mutation, as required for 'overlap extension' (2, 3) and 'megaprimer' (4) mutagenesis. EXON 2-3-4 -547 bp EXON4 PRIMER-182 bp Lanes 1 and 2: 547-bp fragments are exon 2-3-4 PCR products containing either of the two mutations, the 182 bp fragments are the exon 4 double-stranded primers, and the ~500-bp fragments are non-specific products. Lane 3, DNA size marker (pBR322 digested with BstNI + Haeffl).
